Actively Recruiting
Early Infant Micronutrition and Development
Led by Sykehuset Innlandet HF · Updated on 2023-04-18
600
Participants Needed
1
Research Sites
409 weeks
Total Duration
On this page
Sponsors
S
Sykehuset Innlandet HF
Lead Sponsor
U
University of Bergen
Collaborating Sponsor
AI-Summary
What this Trial Is About
Globally, vitamin B12 deficiency is one of the most common micronutrient deficiencies. Poor status is also seen in affluent countries such as in Norway. Vitamin B12 is crucial for normal cell division and differentiation and necessary for the development and myelination of the central nervous system. Deficiency is also associated with impaired fetal and infant growth. In the proposed study we will measure the effect of daily oral vitamin B12 supplementation infants on neurodevelopment. We also aim to measure the impact of B12 supplementation on several other outcomes. Study design: Individually randomized double-blind placebo-controlled trial breastfed infants who will be assigned to a screening group (in which measurements will be obtained immediately) or a control group (in which serum will be stored and measurements done after one year). Pregnant women will be informed about the study during their first antenatal visit at the clinic and that we will re-approach them on their 6-week visit to their public health nurse. Infants who are deficient will be treated with peroral or intramuscular injections with 400 µg cyano-cobalamin. Infants in the control group will not be offered any intervention their blood sample will be stored for one year and then analyzed for the same nutrients as the intervention group. Outcomes: Primary: (i) neurodevelopment in children measured at 12 months of age (ii) growth in children measured by attained weight and length at 12 months. Secondary: (i) neurodevelopment and cognitive functioning in children later in life
CONDITIONS
Official Title
Early Infant Micronutrition and Development
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Availability of informed verbal consent
- Plan to reside in the defined study area for the next 12 months
- Mothers intend to breastfeed their children for at least 8 months, and exclusively for 4 months
You will not qualify if you...
- Severe systemic illness requiring hospitalization
- Growth retardation
- Severe congenital malformations
- Plasma cobalamin concentration below 148 pmol/L (these children will be treated for vitamin B12 deficiency and not included in the randomized trial but included in the cohort design)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Innlandet Hospital Trust
Lillehammer, Norway, 2615
Actively Recruiting
Research Team
C
Carolien Konijnenberg, Ph.D
CONTACT
K
Kjersti S Bakken, Ph.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here